Leiden University Scholarly Publications

Your Search

Enabled Filters

  • (-) = Cancer Research

Refine Results

Resource Type

Availability

Creation Date

Show more

Author

Show more

Language

Search results

  • RSS Feed
(21 - 40 of 74)

Pages

10-year follow-up and biomarker discovery for adjuvant endocrine therapy; results of the TEAM trial
Optimal duration of extended letrozole treatment after 5 years of adjuvant endocrine therapy; results of the randomized phase III IDEAL trial (BOOG 2006-05)
Breast cancer after Hodgkin lymphoma: Influence of endogenous and exogenous gonadal hormones on the radiation dose-response relationship
Tumor Eradication by Cisplatin Is Sustained by CD80/86-Mediated Costimulation of CD8(+) T Cells
LIM Kinase Inhibitor Pyr1 Reduces the Growth and Metastatic Load of Breast Cancers
c-Myb Enhances Breast Cancer Invasion and Metastasis through the Wnt/beta-Catenin/Axin2 Pathway
ER pathway activity as a predictive biomarker for neoadjuvant endocrine therapy
HER2 status as predictive marker for Al vs Tam benefit: A TRANS-AIOG meta-analysis of 12129 patients from ATAC, BIG 1-98 and TEAM with centrally determined HER2
Defining a signature of residual risk following endocrine treatment in the tamoxifen and exemestane adjuvant multinational (TEAM) trial
Tumour immune subtyping as a predictive biomarker for adjuvant endocrine therapy in early breast cancer
ER pathway activity as a predictive biomarker for neoadjuvant endocrine therapy
ER pathway activity as a predictive biomarker for neoadjuvant endocrine therapy
Radiological evaluation of neo-adjuvant endocrine therapy in hormone-receptor positive early breast cancer
Kinase activity profiles distinguish papillary thyroid cancers with and without BRAF V600E mutations
miR-25 Modulates Invasivenessand Dissemination of Human Prostate Cancer Cells via Regulation of alpha(v)- and alpha(6)-Integrin Expression
Sentinel node procedure before or after neoadjuvant chemotherapy in clinically node negative or positive patients; results from 3 phase III studies of the Dutch breast cancer trialists' group (BOOG)
Genetic polymorphisms (SNPs) as predictive markers for paclitaxel-induced peripheral neuropathy (PNP) and capecitabine-induced hand-foot syndrome (HFS) in HER-2 negative metastatic breast cancer patients
Plasma biomarker analysis in patients with HER2-negative locally recurrent or metastatic breast cancer (LR/MBC) treated with first-line bevacizumab (A) and paclitaxel (T) without or with capecitabine (X)
Effects of neoadjuvant chemotherapy with or without zoledronic acid on pathological response: A meta-analysis of randomised trials
Thyroid function is associated with the response to neoadjuvant chemotherapy in breast cancer patients: Results from the NEOZOTAC trial on behalf of the Dutch Breast Cancer Research Group (BOOG 2010-01)

Pages